sc-val-cit-pab

SC-Val-Cit-PAB is a cleavable ADC linker for antibody-drug conjugates (ADCs).

Boc-Val-Cit-OH is a cleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs).

Mal-PEG1-Val-Cit-OH is a cleavable one-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

Mc-Val-Cit-PAB-Cl, a cleavable ADC linker, is utilized in the conjugation of MMAE and antibodies to produce compounds such as antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE), which demonstrate cytotoxicity with IC50s of 3.3 and 0.95 nM against BJAB and WSU cell lines, respectively.

Val-cit-PAB-OH is an ADC linker that is cleavable.

Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mc-Val-Ala-PAB, an effective linker, is utilized in antibody-drug-conjugate (ADC).

Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE . MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization[1].

MC-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Fmoc-Val-Cit-PAB is a linker used for antibody-drug-conjugation (ADC).

MC-Val-Cit-PABC-PNP, also known as Mc-Val-Cit-PABC-PNP, is a cathepsin cleavable ADC peptide linker. For example, FDA approved drug, brentuximab vedotin, adopts this linker. Protein- and peptide-drug conjugates hold a promising stance in the delivery of therapeutic agents by providing distinct advantage of improving therapeutic potential of drugs. Use of specialized linkers makes them unique in their in vivo therapeutic application by providing target tissue-specific release of drug.

Boc-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.

Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.

Fmoc-Val-Ala-PAB-OH (Fmoc-Val-Ala-PAB) is a useful linker for making Antibody-Drug-Conjugation (ADC) conjugate for targeting drug delivery. It is also utilized in the synthesis of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.

TCO-PEG1-Val-Cit-OH is a cleavable 1-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

DBCO-Val-Cit-OH, a cleavable linker compound, finds utility in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate used in antibody-drug conjugates (ADC) that exhibits potent antitumor activity. It employs Retapamulin, a ribosome inhibitor, connected via the ADC linker MC-Val-Cit-PAB.

SC-VC-PAB-DM1 is a drug-linker conjugate used in Antibody-Drug Conjugates (ADC), combining DM1 (Mertansine, a tubulin inhibitor) with the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity.

MC-Val-Cit-PAB-vinblastine is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), featuring vinblastine (a microtubule protein inhibitor) connected through the MC-Val-Cit-PAB [ADC linker].

Endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable four-unit polyethylene glycol (PEG) linker, specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

TCO-PEG1-Val-Cit-PABC-OH, a cleavable 1-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate for antibody-drug conjugates (ADC), featuring the potent antitumor agent rifabutin (a DNA-dependent RNA polymerase inhibitor) connected via the MC-Val-Cit-PAB ADC linker, which endows it with significant antitumor activity.

Mal-PEG4-Val-Cit-PAB-PNP is a cleavable, 4-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG4-Val-Cit-PAB-OH, a cleavable 4-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Acid-propionylamino-Val-Cit-OH is a cleavable linker commonly used in the synthesis of antibody-drug conjugates (ADCs) [1].

Azido-PEG1-Val-Cit-OH is a cleavable, one-unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker used in the synthesis of ADCs[1].

MC-Sq-Cit-PAB-Dolastatin10 is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), incorporating Dolastatin10 (a tubulin polymerization inhibitor) connected via the MC-Sq-Cit-PAB ADC linker.

The chemical compound Mal-Phe-C4-Val-Cit-PAB-DMEA is a cleavable antibody-drug conjugate (ADC) linker that incorporates a Maleimide group. It is commonly employed in the synthesis of ADCs.

OPSS-Val-Cit-PAB-PNP, a cleavable linker used in ADC (antibody-drug conjugates) synthesis [1].

Boc-Val-Ala-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. This cleavable compound efficiently facilitates drug-attachment to antibodies, allowing for targeted therapeutic delivery and release, thus playing a crucial role in ADC development.

MAL-di-EG-Val-Cit-PAB-MMAF is a chemical compound consisting of the linker (MAL-di-EG-Val-Cit-PAB) and the potent tubulin polymerization inhibitor (MMAF, Monomethyl auristatin F) [1].

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

DBCO-Val-Cit-PABC-OH, a cleavable linker, is used in the synthesis of antibody-drug conjugates (ADCs) [1].

Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mal-PEG4-Val-Cit-PAB, a cleavable ADC linker incorporating a Maleimide moiety, finds application in the construction of antibody-drug conjugates (ADCs)[1].

Mal-amido-PEG2-Val-Cit-PAB-OH is a bi-functional polyethylene glycol (PEG) linker, composed of two PEG units, that is cleavable and specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Sq-Cit-PAB-Gefitinib is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), utilizing Gefitinib—an EGFR tyrosine kinase inhibitor—connected through the MC-Sq-Cit-PAB ADC linker.

Mal-PEG1-Val-Cit-PABC-OH is a 1-unit polyethylene glycol (PEG) ADC linker with cleavable properties, used in the synthesis of antibody-drug conjugates (ADCs) to facilitate drug-antibody conjugation[1].

Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3-unit PEG ADC linker used for synthesizing antibody-drug conjugates (ADCs) [1] and also functions as a PEG-based PROTAC linker for PROTAC synthesis [2].

Azido-PEG3-Val-Cit-PAB-OH is a cleavable three-unit polyethylene glycol (PEG) antibody-drug conjugate (ADC) linker used in ADC synthesis [1].

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), consisting of the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the cleavable linker SC-VC-PAB[1].

BCN-PEG1-Val-Cit-OH is a cleavable one-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

MC(C5)-Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

Azido-PEG4-Val-Cit-PAB-OH is a 4-unit PEG ADC linker and a PEG-based PROTAC linker used in the synthesis of antibody-drug conjugates (ADCs)[1] and PROTACs[2].

Boc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

PDP-C1-Ph-Val-Cit is a cleavable ADC linker used in antibody-drug conjugates (ADCs).

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.